That is when a new study of the drug is also planned — details were shared in Novo's earnings presentation, released today, and Redefine 4 study results have been promised for H225. Novo stock ...

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t its wildly popular weight-loss drugs. Novo Nordisk said its fourth ...

Novo Nordisk's U.S.-listed shares are rising 4% in premarket trading after the Ozempic and Wegovy maker's better-than-estimated quarterly results offset slower 2025 sales growth projections amid ...

By Eshe Nelson Reporting from London Novo Nordisk, the Danish pharmaceutical company behind Ozempic and Wegovy, capped off a somewhat turbulent 2024, reporting profit and revenue on Wednesday that ...

Novo expects to continue to grow its reach in 2025, though perhaps not at the magnitude witnessed in 2024. For the full year to come, Novo Nordisk is eyeing sales growth at constant currencies between ...

Novo Nordisk (NVO) reported better-than-expected ... Shares of the Danish drugmaker rose ~4% in European trading, while Eli Lilly (LLY), its main rival in the obesity market, added ~2% in the ...

Good day, and thank you for standing by. Welcome to the full-year 2024 Novo Nordisk earnings conference call. [Operator instructions] Please be advised that today's conference is being recorded.

Novo Nordisk Q4 sales rose 30% to around $12 billion. GLP-1 diabetes sales grew 12% to DKK42.2 billion, while obesity drug sales surged 91% to DKK 21.4 billion. Next: Access Our New, Shockingly ...

Novo Nordisk reported strong data for its next-gen anti-obesity medicine. The Danish company has an excellent weight loss drug pipeline. But it's also diversifying its lineup and offering other ...

LISBON, Feb 5 (Reuters) - Novo Banco's planned initial public offering would be beneficial for the Portuguese banking sector, Bank of Portugal Governor Mario Centeno said on Wednesday, but he ...